Galena Biopharma higher on NeuVax deal with Dr. Reddy's

Galena Biopharma (GALE) adds to Monday's gains, rising 3.6% in premarket action.

The company says it has struck a strategic development and commercialization deal with Dr. Reddy's Laboratories (RDY) for NeuVax in India.

Details are sparse at this juncture.

GALE CEO Mark Ahn says the partnership "is consistent with [GALE's] strategy to expand the clinical utility of NeuVax in unmet medical needs while simultaneously increasing the commercial footprint of this innovative cancer immunotherapy." (PR)

From other sites
Comments (1)
  • Pelion
    , contributor
    Comments (64) | Send Message
    >Details are sparse at this juncture.


    Actually details are non-existent at this juncture and no 8K to view either.


    Includes this line: "Licensing and development terms contracted conditioned upon agreement on ancillary activities."


    Perhaps GALE should have waited for the "ancillary activities" to be finished before issuing a PR with no term details.
    14 Jan 2014, 08:26 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs